Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy

Area of Science:

• Urology
• Oncology
• Pathology

Background:

• Accurate prognostication for prostate cancer is crucial for treatment planning.
• Pathologic T2 (pT2) prostate cancer is a heterogeneous group, and its current subclassifications (pT2a, pT2b, pT2c) are used to refine prognosis.
• The predictive value of these pT2 subclassifications for recurrence-free survival (RFS) after radical prostatectomy requires further investigation.

Purpose of the Study:

• To evaluate the prognostic significance of current pT2 prostate cancer subclassifications.
• To determine if pT2a, pT2b, and pT2c stages predict recurrence-free survival (RFS) after radical prostatectomy.
• To compare the predictive power of pT2 subclassifications with preoperative variables such as prostate-specific antigen (PSA) and biopsy Gleason score.

Main Methods:

• Analysis of 906 patients with pT2 prostate cancer who underwent radical prostatectomy.
• Kaplan-Meier method to estimate 5- and 10-year RFS for pT2a, pT2b, and pT2c groups.
• Multivariate Cox Proportional Hazards models to assess RFS differences and the impact of preoperative PSA and biopsy Gleason score.

Main Results:

• Preoperative PSA and biopsy Gleason score were strong predictors of RFS (P <0.0001).
• While pT2a showed numerically higher RFS than pT2b and pT2c, the difference was not statistically significant (P = 0.13).
• The association between pT2 subclassifications and outcome was diminished after accounting for preoperative PSA and biopsy Gleason score.

Conclusions:

• Current subclassifications of pathologic T2 prostate cancer (pT2a, pT2b, pT2c) lack independent prognostic significance for disease-free survival after radical prostatectomy.
• Preoperative factors, specifically PSA and biopsy Gleason score, are more critical for predicting outcomes in pT2 prostate cancer.
• These findings suggest that pT2 subclassifications may have limited utility in predicting recurrence-free survival.